Lewes, DE -- (SBWIRE) -- 07/10/2014 -- The U.S. Market for Diabetes Monitoring, Treatment and Drug Delivery. The U.S. diabetes monitoring, treatment and drug delivery market will reach $25 billion by 2020, from almost $17 billion in 2013. The increase in patient population as well as increased proportion of diagnosed diabetics will continue to drive the value of this market, with Sanofi, Novo Nordisk and Eli Lilly leading the way.
The Center for Disease Control and Prevention (CDC) reports diabetes as the seventh leading cause of death among Americans as of 2014. The prevalence of the disease has led to a market size for diabetes monitoring, treatment and drug delivery of over $16.7 billion.
The U.S. diabetes monitoring, treatment and drug delivery market includes traditional blood glucose meters, continuous glucose monitoring (CGM) systems, blood glucose test strips, lancets and lancing devices, modern insulin, insulin syringes, modern insulin pens, pen needles, and insulin pumps. The fastest growing area of the diabetes monitoring, treatment and drug delivery market was represented by modern insulin. This expansion will be fuelled by the increasing number of diabetics, modern insulin cannibalizing human insulin and price hikes in the long-acting modern insulin segment.
One of the main trends driving the use of U.S. Market for Diabetes Monitoring, Treatment and Drug Delivery is the modern insulin market. The modern insulin market’s growth is largely attributed to the increasing prices of modern insulin. However, the increasing popularity of insulin pens also contributed to this segment’s fast expansion.
Leading the market for diabetes monitoring, treatment and drug delivery is Sanofi, due to the success in producing and marketing the most successful modern insulin in the U.S. Other major competitors in the market include Novo Nordisk, Eli Lilly, Medtronic, LifeScan and Roche.
The full reports provide a comprehensive analysis including procedure numbers, units sold, market value, forecasts, as well as a detailed competitive market shares and analysis of major players’ success strategies in each market and segment. The reports also cover markets for: traditional blood glucose meters, continuous glucose monitoring systems, blood glucose test strips, lancets and lancing devices, insulin, insulin syringes, insulin pens and insulin pumps as well as emerging technologies.
Spanning over 226 pages, “U.S. Market for Diabetes Monitoring, Treatment and Drug Delivery 2014” report covering The Executive Summary, U.S. Diabetes Diagnosis, Treatment And Drug Delivery Market, Traditional Blood Glucose Meter Market, Traditional Blood Glucose Test Strip Market, Lancet And Lancing Device Market, Continuous Glucose Monitoring Market, Insulin Pump Market, Modern Insulin Market, Insulin Syringe Market, Modern Insulin Pen Market. The report covered 17 companies - Sanofi, Novo Nordisk, Eli Lilly, LifeScan, Medtronic, Roche, Abbott, Becton Dickinson, Bayer, Nipro Diagnostics, Insulet Corporation, Animas, DexCom, Nova Biomedical, Covidien, Owen Mumford, Valeritas.
See Table of contents & Purchase this publication at: - http://www.marketresearchreports.com/idata-research/us-market-diabetes-monitoring-treatment-and-drug-delivery-2014
Find other Reports on United State Market at: http://www.marketresearchreports.com/countries/usa
About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.
Follow us on Google+ at: https://plus.google.com/+Marketresearchreports